The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.
The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback